Navigation Links
Lilly Reports Fourth-Quarter and Full-Year 2009 Results
Date:1/28/2010

INDIANAPOLIS, Jan. 28 /PRNewswire-FirstCall/ --

  • Double-digit revenue growth in Q4 driven by higher volume
  • Weaker dollar results in decreased Q4 gross margin
  • Company delivers Q4 earnings per share of $.83 (reported) or $.91 (pro forma non-GAAP)
  • Full-year 2009 EPS rises to $3.94 (reported) or $4.42 (pro forma non-GAAP)
  • Eight products each exceed $1 billion in annual sales
  • 2010 EPS guidance range reconfirmed at $4.65 to $4.85

Eli Lilly and Company (NYSE: LLY) today announced financial results for the fourth quarter and full year of 2009.

    
    
    $in millions, except per share data 
    
                           Fourth Quarter     %          Full Year       %
                           --------------    ---         ---------      ---
                           2009      2008   Growth    2009      2008   Growth
                           ----      ----   ------    ----      ----   ------
    Total Revenue   
     - Reported          $5,934.2  $5,204.4   14%  $21,836.0 $20,371.9    7%
    Net Income (loss) 
     - Reported             915.4  (3,629.4)  NM     4,328.8  (2,071.9)  NM
    EPS (Loss per share) 
     - Reported               .83     (3.31)  NM        3.94     (1.89)  NM
    
    Total Revenue 
     - Pro forma          5,934.2   5,261.8   13%   21,836.0  20,732.2    5%
    Net Income –  
     Pro forma non-GAAP     999.4   1,116.2  (10)%   4,851.0   4,176.9   16%
    EPS – Pro forma
     non-GAAP           
'/>"/>
SOURCE Eli Lilly and Company
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28

Related medicine technology :

1. FDA Approves Lillys Osteoporosis Drug EVISTA(R) (raloxifene HCl) to Reduce The Risk of Invasive Breast Cancer in Two Populations of Postmenopausal Women
2. Lilly Files for European Approval of ALIMTA(R) (pemetrexed for injection) for First-Line Treatment of Non-Small Cell Lung Cancer
3. Lilly and Glenmark Pharmaceuticals Announce License Agreement
4. Lilly Receives NCQA Design Certification for Depression Care Management Program
5. JDRF and Lilly Partner to Fund Research to Identify Beta Cell Biomarkers
6. FDA Grants Priority Review for Daiichi Sankyo, Lilly Drug, prasugrel
7. Statement from Eli Lilly and Company: Response to Connecticut Attorney General News Release
8. Lilly and Transition Therapeutics Announce Licensing and Collaboration Agreement
9. Lilly Launches Its First Phase III Trial for Treatment of Alzheimers Disease
10. Daiichi Sankyo/Eli Lillys Effient and Astrazenecas Ticagrelor May Offer Advantages in the Treatment of Post-Myocardial Infarction
11. Lilly Submits Cymbalta(R) Supplemental New Drug Application for Chronic Pain to U.S. Food and Drug Administration
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/29/2014)... 29, 2014  Drug development for hepatitis C ... rates and the intense need for curative therapy ... is underway as the market moves away from ... easily-tolerated, interferon-free oral therapies. Logo ... mega blockbuster Sovaldi is the first of these ...
(Date:7/29/2014)... WHEAT RIDGE, Colo. , July 29, 2014 ... technology company focused on developing a proprietary electromagnetic ... announced it entered into an agreement under which ... -based Continuation Investments Limited (COT) in an all-stock ... the Company will initially trade on the Australian ...
(Date:7/29/2014)... , July 29, 2014 China Biologic Products, ... leading fully integrated plasma-based biopharmaceutical company in ... to release second quarter 2014 financial results on Tuesday, ... The Company,s management will hold a conference call ... which is 8:00 p.m., Beijing Time on August 6, ...
Breaking Medicine Technology:A Treatment Revolution is Underway: All-Oral Therapies Transform Global Hepatitis C Antiviral Market 2A Treatment Revolution is Underway: All-Oral Therapies Transform Global Hepatitis C Antiviral Market 3A Treatment Revolution is Underway: All-Oral Therapies Transform Global Hepatitis C Antiviral Market 4The BioFusionary Corporation, Inc. Announces Intent To Complete Reverse Takeover Of Australia-Based Continuation Investments Limited 2The BioFusionary Corporation, Inc. Announces Intent To Complete Reverse Takeover Of Australia-Based Continuation Investments Limited 3China Biologic to Report Second Quarter 2014 Financial Results 2China Biologic to Report Second Quarter 2014 Financial Results 3
... 2011 /PRNewswire-iReach/ -- URINOZINC® Plus with Beta-Sitosterol, ... is now available for purchase at select Walmart stores. ... is the only dietary supplement with a US Patent ... Over 2 million bottles have been sold. ...
... CardioMEMS, Inc ., an Atlanta-based medical device company that ... and communication technology for the human body, today announced ... , has been honored with a Ernst & Young ... category for the Alabama/Georgia/Tennessee region.  According to Ernst & ...
Cached Medicine Technology:Walmart Stores Now Offer URINOZINC® Plus With Beta-Sitosterol 2Dr. Jay Yadav, CardioMEMS Founder & CEO, Named Ernst & Young Entrepreneur of the Year® 2Dr. Jay Yadav, CardioMEMS Founder & CEO, Named Ernst & Young Entrepreneur of the Year® 3
(Date:7/29/2014)... 2014 According to the new ... (Swipe And Area), Material (Optical Prism, Pizeoelectric, Capacitive, ... Commercial Security and Banking & Finance), and Geography ... 2020", published by MarketsandMarkets, the global Fingerprint Sensors ... 2020, growing at a high CAGR of 16.8% ...
(Date:7/29/2014)... best to treat patients after they,ve undergone surgery for ... comes back or provide men with additional radiation therapy ... from Thomas Jefferson University shows that a ... more informed decision. , "We are moving away from ... M.D., Assistant Professor of Radiation Oncology and Cancer Biology ...
(Date:7/29/2014)... repeatedly shown that death rates rise in association with ... in the summer of 2003, for example, resulted in ... by Dr. Alex-andra Schneider at the Institute of Epidemiology ... of extreme temperatures on the number of deaths caused ... both high and low temperatures in the study. , ...
(Date:7/29/2014)... (PRWEB) July 29, 2014 Foot Levelers ... lecturer at the Florida Chiropractic Association (FCA) National Convention ... Effects on the Kinetic Chain Changes on Thursday, August ... talk is focusing on the positive impact functional foot ... such as low back pain, plantar fasciitis, and hammertoes. ...
(Date:7/29/2014)... (PRWEB) July 29, 2014 Catalent ... solutions and advanced delivery technologies for pharmaceutical, biologic, ... Jeff Browne, R&D Director and US Platform Leader ... of Absorption-Limited Drugs with Lipid-Based Formulations using Soft ... Meeting of the Japan Society of Drug Delivery ...
Breaking Medicine News(10 mins):Health News:Fingerprint Sensors Market by Type (Swipe And Area) Estimated to Reach $14.35 Billion by 2020 - New Report by MarketsandMarkets 2Health News:Fingerprint Sensors Market by Type (Swipe And Area) Estimated to Reach $14.35 Billion by 2020 - New Report by MarketsandMarkets 3Health News:Fingerprint Sensors Market by Type (Swipe And Area) Estimated to Reach $14.35 Billion by 2020 - New Report by MarketsandMarkets 4Health News:Genomic analysis of prostate cancer indicates best course of action after surgery 2Health News:Mortality rates increase due to extreme heat and cold 2Health News:Foot Levelers CEO Kent Greenawalt Speaking at FCA Convention 2Health News:Catalent Expert to Present on Enhancing Bioavailability of Poorly Absorbed Drugs at Japan Society of Drug Delivery Systems 2
... Mich., Nov. 19 Perrigo Company,(Nasdaq: PRGO ... by Sanofi-Aventis (NYSE: SNY ) against Barr ... BRL ). The suit was brought in,the ... filing of an ANDA,for Triamcinolone Acetonide Nasal Spray containing ...
... has Decreased By More than One-Fourth , ... federal government show that cigarette consumption in the U.S. has ... over the past decade, which marks a major milestone in ... of Attorneys General (NAAG) and the American Legacy Foundation (R) ...
... Mass., Nov. 19 Graeme Green Ph . ... discuss the results of the JUPITER study presented at the American ... , The results of the 17,802-patient trial demonstrated ... attack and death among patients who seemed healthy but showed high ...
... Appoints Paul Hamelin as President , ... Savient Pharmaceuticals, Inc. (Nasdaq: SVNT ) today ... BLA Oversight Committee ("the Committee")to oversee the regulatory and ... The Committee will be comprised of independent Board members ...
... PORT ORCHARD, Wash., Nov. 19 Stayhealthy, Inc. and ... program with the,Washington Fire Chief,s Fire Rescue Wellness Corporation ... firefighters. , "The ... top concern," said,Chief Wayne Senter, Fire Chief of South ...
... People in the middle of,separation or divorce often ... are shattered; the hope and joy that normally,accompany ... This year,s,economic downturn will add even more pressure ... already-difficult financial circumstances. , ...
Cached Medicine News:Health News:Perrigo Acknowledges Settlement of NASACORT(R) AQ Nasal Spray Patent Litigation 2Health News:Perrigo Acknowledges Settlement of NASACORT(R) AQ Nasal Spray Patent Litigation 3Health News:America Reaches Major Anti-Smoking Milestone 2Health News:America Reaches Major Anti-Smoking Milestone 3Health News:America Reaches Major Anti-Smoking Milestone 4Health News:America Reaches Major Anti-Smoking Milestone 5Health News:Analyst Available to Comment on New JUPITER Study That Shows AstraZeneca's Crestor Significantly Reduces CV Risk 2Health News:Savient's Board of Directors Forms a Board Committee to Oversee the Regulatory and Pre-Launch Activities for Pegloticase 2Health News:Savient's Board of Directors Forms a Board Committee to Oversee the Regulatory and Pre-Launch Activities for Pegloticase 3Health News:Savient's Board of Directors Forms a Board Committee to Oversee the Regulatory and Pre-Launch Activities for Pegloticase 4Health News:Savient's Board of Directors Forms a Board Committee to Oversee the Regulatory and Pre-Launch Activities for Pegloticase 5Health News:Savient's Board of Directors Forms a Board Committee to Oversee the Regulatory and Pre-Launch Activities for Pegloticase 6Health News:Savient's Board of Directors Forms a Board Committee to Oversee the Regulatory and Pre-Launch Activities for Pegloticase 7Health News:Savient's Board of Directors Forms a Board Committee to Oversee the Regulatory and Pre-Launch Activities for Pegloticase 8Health News:Washington Fire Firefighters Launch First of Its Kind Pilot Program on Health and Fitness 2Health News:Washington Fire Firefighters Launch First of Its Kind Pilot Program on Health and Fitness 3Health News:Holiday Season Amplifies Hurt of Separation and Divorce: Economic Woes Add to Pressure 2
... 2 gel holder cassettes, 4 fiber pads, ... buffer chamber, lid with cables, and instructions. ... of Bio-Rad's modular mini electrophoresis system (see ... of mini gels. Its modular electrode assembly ...
... 200 power supply. Flexibility ... Quantitative Transfers. Native Enzyme, ... Faster, Higher-Efficiency Transfers via ... Transfers with Movable Electrodes. ...
... gel holder cassettes, cell with ... pads, blot absorbent paper (15 ... transfer cell, used with the ... efficient, high-intensity electrophoretic transfers. The ...
... for running Criterion precast gels and ... blotter fit for use with the ... the Criterion blotter combines excellent blotting ... Trans-Blot system and the ease-of-use of ...
Medicine Products: